ReviewCurrent opinion in supportive and palliative care2012
Novel drugs to ameliorate gastrointestinal normal tissue radiation toxicity in clinical practice: what is emerging from the laboratory?
Review in Current opinion in supportive and palliative care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Interferon b drives intestinal regeneration after radiation.Science advances · 2021Article
- An Active Fraction ofFrontiers in cell and developmental biology · 2021Article
- Review
- Expanding the therapeutic index of radiation therapy by normal tissue protection.The British journal of radiology · 2019Review
- Cebpd Is Essential for Gamma-Tocotrienol Mediated Protection against Radiation-Induced Hematopoietic and Intestinal Injury.Antioxidants (Basel, Switzerland) · 2018Article
- Targeting p53-dependent stem cell loss for intestinal chemoprotection.Science translational medicine · 2018Article
- The GS-nitroxide JP4-039 improves intestinal barrier and stem cell recovery in irradiated mice.Scientific reports · 2018Article
- Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care: a decade of progress.Current opinion in supportive and palliative care · 2016Article
- Vitamin E Analogs as Radiation Response Modifiers.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Investigation into the role of the cholinergic system in radiation-induced damage in the rat liver and ileum.Journal of radiation research · 2014Article
- Molecular dynamics guided design of tocoflexol: a new radioprotectant tocotrienol with enhanced bioavailability.Drug development research · 2014Article
- Article
- Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures.Journal of radiation research · 2013Review
- Effects of radiation on the epidermal growth factor receptor pathway in the heart.International journal of radiation biology · 2013Article
- Mesenchymal stem cell therapy stimulates endogenous host progenitor cells to improve colonic epithelial regeneration.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewTo give an overview of promising novel agents under development for the prevention and reduction of gastrointestinal radiation injury. RECENT
findingsCurrently, several novel agents are being tested as drugs to prevent or reduce gastrointestinal radiation injury. These drugs may not only prevent injury, but also mitigate toxicity, that is, reduce injury after radiation exposure has occurred. Promising novel agents include the somatostatin analogue SOM230, growth factors, agents acting on the toll-like receptor 5 pathway, endothelial protectants, and the vitamin E analogue γ-tocotrienol. SUMMARY: Gastrointestinal radiation injury is the most important dose-limiting factor during radiotherapy of the abdomen or pelvis. It may severely affect the quality of life both during radiotherapy treatment and in cancer survivors. To date, there are no agents that can prevent or reduce intestinal radiation injury. Hence, there is an urgent need for the development of novel drugs to ameliorate intestinal toxicity during and after radiotherapy. This review summarizes the several agents that have been shown to reduce intestinal radiation injury in animals. Further research is needed to investigate their safety and efficacy in patients receiving radiotherapy for abdominal or pelvic tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.